瑞芬太尼对心脏手术后热觉与痛觉阈值的短期和长期影响:一项随机对照试验
该单盲随机对照试验纳入126例18至85岁经胸骨正中切开行心脏手术的患者,比较术中持续输注瑞芬太尼与间断芬太尼对术后3天和12个月热觉与痛觉阈值的影响。结果显示两组在术后3天和12个月的热觉和痛觉阈值均无显著差异(P > 0.05),未发现痛觉敏感性改变的显著预测因素。结论提示瑞芬太尼在慢性胸部疼痛发展中作用较小,但慢性胸部疼痛发生率较高及其对生活质量的影响仍是挑战。
要点
- 瑞芬太尼与芬太尼组术后3天和12个月的热觉与痛觉阈值无显著差异。
- 未发现术后12个月痛觉敏感性改变的显著预测因素。
- 瑞芬太尼在慢性胸部疼痛发展中作用较小,但慢性胸部疼痛问题仍具挑战。
核心结论
- 本研究未能证实既往关于瑞芬太尼使用后1年痛觉敏感性增加的报道。
- 瑞芬太尼在慢性胸部疼痛发展中作用较小。
- 慢性胸部疼痛发生率较高及其对生活质量的影响仍是挑战。
研究设计与样本
- 单盲随机对照试验,在荷兰一家三级教学医院于2014至2016年进行。
- 共纳入126例18至85岁经胸骨正中切开行心脏手术(冠状动脉旁路移植和/或瓣膜置换)的患者。
- 患者随机接受术中持续瑞芬太尼输注或按需间断芬太尼,均联合丙泊酚标准化麻醉及预定时间点间断静脉芬太尼。
主要发现
- 瑞芬太尼组与芬太尼组术后3天和12个月的热觉和冷觉检测阈值及痛觉阈值均无显著差异(P > 0.05)。
- 未识别出术后12个月痛觉敏感性改变的显著预测因素。
临床怎么用
- 基于本研究,术中瑞芬太尼使用与术后短期和长期热觉及痛觉阈值改变无关。
- 瑞芬太尼在慢性胸部疼痛发展中的作用较小,临床可据此评估其长期痛觉影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical relevance of the suggested hyperalgesic effects of remifentanil is still unclear, especially in the long term. OBJECTIVE: The current study evaluated the impact of remifentanil on thermal thresholds 3 days and 12 months after surgery, measured with Quantitative Sensory Testing. DESIGN: A single-blind, randomised controlled trial. SETTING: A tertiary care teaching hospital in The Netherlands, from 2014 to 2016. PATIENTS: A total of 126 patients aged between 18 and 85 years, undergoing cardiothoracic surgery via sternotomy (coronary artery bypass grafts and/or valve replacement) were included. Exclusion criteria were BMI above 35 kg m, history of cardiac surgery, chronic pain conditions, neurological conditions, allergy to opioids or paracetamol, language barrier and pregnancy. INTERVENTIONS: Patients were allocated randomly to receive intra-operatively either a continuous remifentanil infusion or intermittent intra-operative fentanyl as needed in addition to standardised anaesthesia with propofol and intermittent intravenous fentanyl at predetermined time points. MAIN OUTCOME MEASURES: Warm and cold detection and pain thresholds 3 days and 12 months after surgery. In addition the use of remifentanil, presence of postoperative chronic pain, age, opioid consumption and pre-operative quality of life were tested as a predictor for altered pain sensitivity 12 months after surgery. RESULTS: Both warm and cold detection, and pain thresholds, were not significantly different between the remifentanil and fentanyl groups 3 days and 12 months after surgery (P > 0.05). No significant predictors for altered pain sensitivity were identified. CONCLUSION: Earlier reports of increased pain sensitivity 1 year after the use of remifentanil could not be confirmed in this randomised study using Quantitative Sensory Testing. This indicates that remifentanil plays a minor role in the development of chronic thoracic pain. Still, the relatively high incidence of chronic thoracic pain and its accompanying impact on quality of life remain challenging problems. TRIAL REGISTRATION: The study was registered at EudraCT (ref: 2013-000201-23) and ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT02031016).
引用
- de Hoogd S, Valkenburg AJ, van Dongen EPA, et al. Short- and long-term impact of remifentanil on thermal detection and pain thresholds after cardiac surgery: A randomised controlled trial. Eur J Anaesthesiol. 2019. PMID: 30211725. doi:10.1097/EJA.0000000000000887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。